About Drugs in Context

Drugs in Context is an open access, peer-reviewed, continuous publication of international standing. It is a member of the Directory of Open Access Journals (https://doaj.org/). It is listed on PubMed and all articles are free-to-view/download immediately on PubMed Central.

Articles: we publish high-quality, peer-reviewed original research papers and topical review articles covering the latest evidence and innovations in drug treatment across all therapeutic areas.

Peer review: we conduct single-blind external peer review on all manuscripts with comments from at least two peer reviewers. Our aim is to obtain a first editorial decision within 3 weeks of manuscript submission and online publication within 3 weeks of acceptance.

Featured Article

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy

Yue Zhao MD, Rishi P Singh MD

Articles 2018

Advances in the use of PARP inhibitor therapy for breast cancer

Kelly E McCann MD, PhD, Sara A Hurvitz MD

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment

Sarah L Anderson PharmD, Joel C Marrs PharmD

Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors

Daniel I G Cubero MD, PhD, Beatrice Martinez Zugaib Abdalla MD, Jean Schoueri, Fabio Iazetti Lopes, Karine Corcione Turke, Jose Guzman MD, Auro Del Giglio MD, PhD, Carlos D’Apparecida Santos Machado Filho MD, PhD, Vanessa Salzano MD, Dolores Gonzalez Fabra MD

Febrile seizures: an overview

Alexander KC Leung MBBS, FRCPC, FRCP (UK and Irel), FRCPCH, FAAP, Kam Lun Hon MD, FAAP, FCCM, Theresa NH Leung MBBS, FRCPCH, FHKAM (Paed)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?

Alfredo Addeo MD, Giulio Metro MD